Ser204
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser204  -  CSDA (human)

Site Information
EEEGsGssEGFDPPA   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 3181085

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 , 6 , 7 , 8 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 )
Disease tissue studied:
breast cancer ( 4 ) , HER2 positive breast cancer ( 2 ) , luminal A breast cancer ( 2 ) , luminal B breast cancer ( 2 ) , breast cancer, triple negative ( 2 ) , cervical cancer ( 17 ) , cervical adenocarcinoma ( 17 ) , leukemia ( 10 ) , acute myelogenous leukemia ( 10 ) , lung cancer ( 7 ) , non-small cell lung cancer ( 7 ) , melanoma skin cancer ( 3 ) , T-ALL ( 1 )
Relevant cell line - cell type - tissue:
'muscle, skeletal' ( 11 ) , 293 (epithelial) [AT1 (human), transfection] ( 15 ) , 293E (epithelial) ( 12 ) , A498 (renal) ( 16 ) , breast ( 2 ) , Calu 6 (pulmonary) ( 7 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 8 ) , H2009 (pulmonary) ( 7 ) , H2077 (pulmonary) ( 7 ) , H2887 (pulmonary) ( 7 ) , H322 (pulmonary) ( 7 ) , H322M (pulmonary) ( 7 ) , HCC1359 (pulmonary) ( 7 ) , HCC2279 (pulmonary) ( 7 ) , HCC366 (pulmonary) ( 7 ) , HCC4006 (pulmonary) ( 7 ) , HCC78 (pulmonary) ( 7 ) , HCC827 (pulmonary) ( 7 ) , HeLa (cervical) ( 14 , 18 , 20 ) , HeLa S3 (cervical) ( 17 ) , HMLER ('stem, breast cancer') ( 4 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 4 ) , HOP62 (pulmonary) ( 7 ) , HUES-9 ('stem, embryonic') ( 13 ) , Jurkat (T lymphocyte) ( 6 , 19 ) , K562 (erythroid) ( 18 ) , KG-1 (myeloid) ( 10 ) , LCLC-103H (pulmonary) ( 7 ) , LOU-NH91 (squamous) ( 7 ) , NCI-H1395 (pulmonary) ( 7 ) , NCI-H1648 (pulmonary) ( 7 ) , NCI-H2030 (pulmonary) ( 7 ) , NCI-H2172 (pulmonary) ( 7 ) , NCI-H460 (pulmonary) ( 7 ) , T-ALL (T lymphocyte) ( 1 ) , WM239A (epidermal) ( 3 )

References 

1

Degryse S, et al. (2017) Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia. Leukemia
28852199   Curated Info

2

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

3

Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615
25850435   Curated Info

4

Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90
24782546   Curated Info

5

Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96
23911959   Curated Info

6

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

7

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

8

Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70
22496350   Curated Info

9

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

10

Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56
22115753   Curated Info

11

Lundby A, et al. (2012) Quantitative maps of protein phosphorylation sites across 14 different rat organs and tissues. Nat Commun 3, 876
22673903   Curated Info

12

Hsu PP, et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-22
21659604   Curated Info

13

Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3
21406692   Curated Info

14

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

15

Xiao K, et al. (2010) Global phosphorylation analysis of beta-arrestin-mediated signaling downstream of a seven transmembrane receptor (7TMR). Proc Natl Acad Sci U S A 107, 15299-304
20686112   Curated Info

16

Schreiber TB, et al. (2010) An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Mol Cell Proteomics 9, 1047-62
20071362   Curated Info

17

Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3
20068231   Curated Info

18

Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808
19651622   Curated Info

19

Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46
19690332   Curated Info

20

Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7
18669648   Curated Info